front 1 how much nutrients lost in feces (%) | back 1 5% |
front 2 IF definition | back 2 The reduction of gut function below the minimum necessary for the absorption of macronutrients and/or fluids and electrolytes that interavenous support is required to maintain health and growth |
front 3 Intestinal insuffiency | back 3 the reduction in the absorptive function of the gut that does not require intravenous supplementation to maintain heath or growth |
front 4 (true or false) patients receiving IV nutrition means intestinal failure | back 4 false patients receiving IV nutrition not necessarily intestinal failure |
front 5 Functional or chronological classification of IF | back 5 Type 1 (self-limiting, short-term) (inflammation, post operative ileus) Type 2 (prolonged) (GI complications, abdominal sepsis, enterocutaneous fistula) Type 3 (chronic) (volvous, NEC, SBS, crohns) |
front 6 Pathological Classification of IF | back 6
|
front 7 Normal length of small bowel (adults and pediatrics) Cutoff for SBS | back 7 Pediatrics ~ 2 m Adults ~ 2.75-8 m <200cm |
front 8 Genetic Predisposition to Crohn's Disease | back 8 – Concordance rates: MZ twin 30%; DZ twins 4% – NOD2, IL23 |
front 9 SBS types | back 9
|
front 10 Mucus fistula refeeding | back 10 Reinfuses proximal stoma effluent into the distal bowel to enhance nutrient absorption, promote bowel adaptation, and reduce dependence on parenteral nutrition.
|
front 11 Intestinal dysmotility main cause | back 11 Chronic Intestinal Pseudo-Obstruction (CIPO)
|
front 12 St. Mark's solution contents | back 12
|
front 13 Pharmacological treatment of IF | back 13 1. Anti-motility Drugs (Codeine Phosphate, Loperamide) - increase transit time and absorption 2. Anti-secretory Drugs (Proton Pump Inhibitors, Octreotide) - reduce diarrhoea 3. Teduglutide (Glucagon-Like Peptide-2 analogue) - improve intestinal adaptation |